

DAFTAR PUSTAKA

1. Malak R, Kotwicka M, Wasielewska AK and W ME. Motor skill, cognitive development and balance function of children with Down syndrome. Annual of Agricultural and environment Medicine. 2013; 20: 803-6.
2. Khalil A and Pandya A. Screening for Down syndrome. J Obstet Gynecol India. 2006; 56: 205-11.
3. Brockmeyer D. Down's Syndrome and craniovertebral instability: topic review and treatment recommendations. Nepal Journal of Neuroscience. 2005; 2: 52-8.
4. Ram G and Chinen J. Infections and immunodeficiency in Down syndrome. Clinical and Experimental Immunology. 2011; 164: 9-16.
5. Dutta S, Nandagopal K, Gangopadhyay PK and Mukhopadhyay K. Molecular aspects of Down syndrome. Indian Pediatrics. 2005; 42: 339-44.
6. Wiseman FK, Alford KA, Tybulewicz V and Fisher E. Down Syndrome- Recent progress and future prospect. Human Molecular Genetic. 2009; 18: 75-83.
7. Morris JK, Mutton DE and Alberman E. Revised estimates of the maternal age specific live birth prevalence of Down's syndrome. J Med Screen. 2002; 9: 2-6.
8. Mengenal Down Syndrom. In: Persatuan Orangtua dengan Anak dengan Down Syndrom. Diunduh dari : <http://potads.com/downsyndrome.php>.
9. Idris R, Anggoro B and Hartamto H. Penderita sindrom Down berdasarkan analisis kromosom di Laboratorium Biologi Fakultas Kedokteran Universitas Indonesia antara tahun 1992-2004. Profesi Medika. 2006; 6: 3-5.

10. Chundrayetti E. Hubungan Polimorfisme gen DYRK1A SNP rs 2154545 dan rs8139276 dan protein TAU dengan retardasi mental pada sindrom Down (disertasi). Universitas Andalas; 2017
11. Netto C.B.O, Portela L.V, Fereirra C.T, et al. Ontogenetic changes in serum S100B in Down syndrome patients. *Clinical Biochemistry*. 2005; 38: 433-5.
12. Donato R, Sorci G, Riuzzi F AC, et al. S100B's double life: Intracellular regulator and extracellular signal. *Biochimica et Biophysica Acta*. 2009; 1793.
13. Azmitia P.M.W, Shapiro L, McGoey LB and Azmitia EC. Role of S100b overexpression in Down syndrome: Translational and human studies. Workshop on Cognition in Down Syndrome Molecular, Cellular and Behavioral Features and the Promise of Pharmacotherapies. Washington,DC: Linda Crnic Institute for Down Syndrome, 2013, p. 22.
14. Kato K, Suzuki F, Kurobe N, Okajima K, Ogasawara N, Nagaya M, et al. Enhancement of S-100 beta protein in blood of patients with Down's syndrome. *J Mol Neurosci* 1990;2:109-13.
15. Espacito G, Scuderi C, Lu J, et al. S100B induces tau protein hyperphosphorylation via Dickkopf-1 up-regulation and disrupts the Wnt pathway in human neural stem cells. *J Cell Mol Med*. 2008; 12: 914-27.
16. Habib FA. Antenatal screening strategies for Down syndrome: Analysis of existing protocols and implications in the Kingdom of Saudi Arabia. *British Journal of Medicine & Medical Research* 2011;1:105-21.

17. Descartes M, Carroll AJ. Cytogenetics. In: Kliegman RM, Behrman RE, Jenson HB, Stanton BF, eds. Nelson Textbook of Pediatrics, 18 ed. Philadelphia: Saunders Elsevier; 2007.
18. Barkoukis A, Reiss NS, Dombek M. Childhood disorder: mental retardation. 2008 (diakses 18 Januari 2015). Diunduh dari: [Http://www.mentalhelp.net](http://www.mentalhelp.net).
19. Capone GT. Down syndrome: advances in molecular biology and the neurosciences. *Developmental and Behavioral Pediatrics* 2001;22.
20. Tejedor FJ. MNB / DYRK1A as a multiple regulator of neuronal development. *FEBS Journal*. 2011;278: 223–35.
21. Ahmed M, Stenber A, Hall G, Thomas A, Smith O. Natural history of GATA1 mutation in Down Syndrome. 2004;103:2480-89.
22. Leshin L. Trisomy 21: The story of Down syndrome. 2009 (diakses 1 Januari 2105) Diunduh dari : <http://www.ds-health.com/trisomy.htm>.
23. Marder E, Denniss J. Medical management of children with Down's syndrome. *Current Paediatrics* 2001;11:57-63.
24. Tarek M. The baby with Down syndrome. *ASJOG*. 2005;2:362-5.
25. Banjar HH. Down's syndrome and pulmonary arterial hypertension. *PVRI Review* 2009;1:213-6.
26. Weijerman WE, de Winter JP. The care of children with Down syndrome. *Eur J Pediatr* 2010;169:1445-52.
27. Kumin L. Speech intelligibility and childhood verbal apraxia in children with Down syndrome. Maryland: The Down Syndrom Educational Trust;2006.

28. World Health Organization. International statistical classification of disease and related health problems. 10th revision. Geneva: World Health Organization; 1992.
29. American Association on Mental Retardation. Mental retardation: definition, classification and system of support. 9th ed. Washington (DC): American Association on Mental Retardation; 1992.
30. American Psychiatric Association. Diagnostic and statistical manual of mental disorders fifth edition (DSM-5). Washington DC: American Psychiatric Publishing; 2013.
31. Rachidi M. Genetic mechanisms of the mental retardation in down syndrome. 2010. Diunduh dari [Http://www.scitopics.com](http://www.scitopics.com).
32. Lumbantobing SM. Anak dengan mental terbelakang. Jakarta: balai penerbit FKUI ; 2001.
33. Vasconcelos MM. Mental retardation. J pediatr.2004; 80:71-82.
34. Cerro SG, Martinez P, Vidal V, Corrales A, Florez J, Vidal R, et al. Overexpression of Dyrk1A Is Implicated in Several Cognitive, Electrophysiological and Neuromorphological Alterations Found in a Mouse Model of Down Syndrome. Plos ONE. 2014;9:1-16.
35. American academy of child and adolescent psychiatry. Children who are mentally retarded. 2004 (diakses 1 Januari 2015). Diunduh dari: [Http://www.aacap.org](http://www.aacap.org).
36. Walker WO. Mental retardation: overview and diagnosis. Peds in review. 2006;27: 204-12.

37. Rachidi M, Lopes. Mental retardation and human chromosome 21 gene overdosage : from functional genomic and molecular mechanisms towards prevention and treatment of the neuropathogenesis of Down Syndrome. *Genomics, Proteomics, and the Nervous System*. Clelland. 2011. p 21-28.
38. Heizman WC, Fritz G and Schafer BW. S100 proteins : structure, functions and pathology. *Frontiers in Bioscience*. 2002; 7: 1356-68.
39. Sedaghat F and Notopulos A. S100 protein family and its application in clinical practice. *Hippokratia*. 2008; 12: 198-204.
40. Al-Ayadhi LY, Mostafa GH. A lack of association between elevated serum levels of S100B protein and autoimmunity in autistic children. *Journal of neuroinflammation* 2012;9;54-52.
41. Reali C, Pillai R, Saba F, Cabras S, Michetti F, Sogos V. S100B modulates growth factors and costimulatory molecules expression in cultured human astrocytes. *Journal of neuroimmunology* 2011;243:95-9.
42. Leclerc E, Fritz G, Vetter SW, Heizmann CW. Binding of S100 proteins to RAGE: An update. *Biochimica et Biophysica Acta* 2009;1793:993-1007.
43. Liu L, Zhou HY, He L, Song JW, Nie WX, SU ZY. Measurement of urinary S100B protein level and lactat/creatinin ratio in early detection of neonatal HIE. *World J Pediatr* 2006;2:270-6.
44. Michetti F, Corvino V, Geloso MC, Lattanzi W, Bernardini C, Serpero L, Gazzolo D. The S100B protein in biological fluids: more than a lifelong biomarker of brain distress. *Journal neurochemistry* 2012;120:644-59.

45. Marenholz I, Heizmann CW, Fritz G. S100 Proteins in Mouse and Man: from Evolution to Function and Pathology. *Biochemistry Biophysical Research Community*.2004;322:1111–22.
46. Donato R. S100:A Multigenic Family of Calcium-Modulated Proteins of The EF Hand Type with Intracellular and Extracellular Functional Roles. *International Journal Biochemistry Cell Biology*.2001;33:637–68.
47. S. Korfiatis, G. Stranjalis, A. Papadimitriou, C. Psachoulia, G. Daskalakis, A. Antsaklis, D.E. et al. Serum S-100B protein as a biochemical marker of brain injury: a review of current concepts, *Curr. Med. Chem.* 2006;13:3719–31.
48. G.S. Mazzini, D.V. Schaf, E.R. Vinadé, E. Horowitz, R.S. Bruch, L.M. Brunm, et al. Increased S100B serum levels in dilated cardiomyopathy patients, *J. Card. Fail.*2007;13:850–4.
49. P. Nardin, F. Tramontina, M.C. Leite, A.C. Tramontina, A. Quincozes-Santos, L.M. de Almeida, A.M. et al. S100B content and secretion decrease in astrocytes cultured in high-glucose medium, *Neurochem. Int.*2007;50: 774–782.
50. Gonçalves, D., Karl, J., Leite, M., Rotta, L., Salbego, C., Rocha, E. et al. High glutamate decreases S100B secretion stimulated by serum deprivation in astrocytes. *Neuroreport*.2002;27;1533–35.
51. D. Kögel, M. Peters, H.G. König, S.M. Hashemi, N.T. Bui, V. Arolt, et al. S100B potently activates p65/c-Rel transcriptional complexes in hippocampal neurons: clinical implications for the role of S100B in excitotoxic brain injury, *Neuroscience*.2004;127:913–20.

52. P. Pichiule, J.C. Chavez, A.M. Schmidt, S.J. Vannucci. Hypoxia-inducible factor-1 mediates neuronal expression of the receptor for advanced glycation end products following hypoxia/ischemia, *J. Biol. Chem.* 2007;282:36330–40.
53. K.R. Schmitt, C. Kern, P.E. Lange, F. Berger, H. Abdul-Khaliq, S. Hendrix. S100B modulates IL-6 release and cytotoxicity from hypothermic brain cells and inhibits hypothermia-induced axonal outgrowth, *Neurosci. Res.* 2007;59:68–73.
54. R. Businaro, S. Leone, G. Sorci, R. Donato, G.M. Lauro, L. Fumagalli. S100B protects LAN-5 neuroblastoma cells against A β amyloid-induced neurotoxicity via RAGE engagement at low doses but increases A β amyloid neurotoxicity at high doses, *J. Neurosci. Res.* 2006;83:897–906.
55. E. Leclerc, G. Fritz, M. Weibel, C.W. Heizmann, A. Galichet. S100B and S100A6 differentially modulate cell survival by interacting with distinct RAGE (receptor for advanced glycation end products) immunoglobulin domains, *J. Biol. Chem.* 2007;282:31317–31.
56. A.M. Vincent, L. Perrone, K.A. Sullivan, C. Backus, A.M. Sastry, C. Lastoskie, et al. Receptor for advanced glycation end products activation injures primary sensory neurons via oxidative stress. *Endocrinology.* 2007;148:548–58.
57. M. Rothermundt, G. Ponath, V. Arolt. S100B in schizophrenic psychosis. *Int. Rev. Neurobiol.* 2004;59: 445–70.
58. G. Poelmans, J.J. Engelen, J. Van Lent-Albrechts, H.J. Smeets, E. Schoenmakers, B. Franke, et al. Identification of novel dyslexia candidate

- genes through the analysis of a chromosomal deletion. *Am. J. Med. Genet. B. Neuropsychiatr. Genet.* 2008;150:140-7.
59. G. Esposito, J. Imitola, J. Lu, D. De Filippis, C. Scuderi, V.S. Ganesh, et al. Genomic and functional profiling of human Down syndrome neural progenitors implicates S100B and aquaporin 4 in cell injury. *Hum. Mol. Genet.* 2008;17:440–57.
60. R.E. Mrazek, W.S. Griffin. Trisomy 21 and the brain. *J. Neuropathol. Exp. Neurol.* 2004;63:679–685.
61. Lam V, Albrecht MA, Takechi R, Giles C, James AP, Foster JK et al. The serum concentration of the calcium binding protein S100B is positively associated with cognitive performance in older adults. *Frontiers in Aging Neuroscience.* 2013;6:1-6
62. Kleindienst, A., McGinn, M.J., Harvey, H.B., Collelo, R.J., Hamm, R.J., and Bullock, M.R. Enhanced hippocampal neurogenesis by intraventricular S100B infusion is associated with improved cognitive recovery after traumatic brain injury. *J. Neurotrauma.* 2005;22:645-55.
63. Pedersen A, Diedrich M, Kaestner F, Koelkebeck K, Ohrmann P, Ponath G, et al. Memory impairment correlates with increased S100B serum concentrations in patients with chronic schizophrenia. *Prog Neuropsychopharmacol Biol Psychiatry.* 2008;32:1789-92.
64. Zhai J, Zhang Q, Cheng L, Chen M, Wang K, Liu Y et al. Risk variants in the S100B gene, associated with elevated S100B levels, are also associated with visuospatial disability of schizophrenia. *Behavioural Brain Research.* 2011;217: 363-8

65. Li YC, Xi CH, An YF, Dong, Zhou M. Perioperative inflammatory response and protein S-100b concentrations–relationship with post-operative cognitive dysfunction in elderly patients. *Acta Anaesthesiol Scand.*2012;56;595-600
66. Nagdyman N, Grimmer I, Scholz T, Muller C, Obladen M. Predictive Value of Brain-Specific Proteins in Serum for Neurodevelopmental Outcome after Birth Asphyxia. *International Pediatric Research Foundation.*2003;54;270-5
67. Boussard CN, Lundin A, Karlstedt D, Edman G, Bartfai A, Borg J. S100 and cognitive impairment after mild traumatic brain injury. *J Rehabil Med.*2005;37:53-57
68. Pham N, Fazio V, Cucullo L, Teng Q, Biberthaler P, et al. Extracranial Sources of S100B Do Not Affect Serum Levels. *PLOS ONE.* 2010; 5(10): 10
69. Portela LV, Tort AB, Schaf DV, Ribeiro L, Nora DB, Walz R et al. The Serum S100B Concentration Is Age Dependent. *Clinical Chemistry.* 2002; 48:950-2

